Dataset Information


GSK3? inhibition activates the CDX/HOX pathway and promotes hemogenic endothelial progenitor differentiation from human pluripotent stem cells.

ABSTRACT: WNT/?-CATENIN signaling promotes the hematopoietic/endothelial differentiation of human embryonic stem cells and human induced pluripotent stem cells (hiPSCs). The transient addition of a GSK3? inhibitor (GSKi) has been found to facilitate in vitro endothelial cell differentiation from hESCs/hiPSCs. Because hematopoietic and endothelial cells are derived from common progenitors (hemogenic endothelial progenitors [HEPs]), we examined the effect of transient GSKi treatment on hematopoietic cell differentiation from hiPSCs. We found that transient GSKi treatment at the start of hiPSC differentiation induction altered the gene expression profile of the cells. Multiple CDX/HOX genes, which are expressed in the posterior mesoderm of developing embryos, were significantly upregulated by GSKi treatment. Further, inclusion of the GSKi in a serum- and stroma-free culture with chemically defined medium efficiently induced HEPs, and the HEPs gave rise to various lineages of hematopoietic and endothelial cells. Therefore, transient WNT/?-CATENIN signaling triggers activation of the CDX/HOX pathway, which in turn confers hemogenic posterior mesoderm identity to differentiating hiPSCs. These data enhance our understanding of human embryonic hematopoietic/endothelial cell development and provide a novel in vitro system for inducing the differentiation of hematopoietic cells from hiPSCs.

SUBMITTER: Kitajima K 

PROVIDER: S-EPMC5160023 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3462245 | BioStudies
2020-01-01 | S-EPMC7578858 | BioStudies
2016-01-01 | S-EPMC4729203 | BioStudies
2018-01-01 | S-EPMC6234921 | BioStudies
2018-01-01 | S-EPMC5910050 | BioStudies
1000-01-01 | S-EPMC6290105 | BioStudies
2020-01-01 | S-EPMC7659123 | BioStudies
2019-08-21 | GSE118947 | GEO
2020-01-01 | S-EPMC7788460 | BioStudies
2021-05-26 | S-SCDT-EMBOR-2020-50535V1 | BioStudies